Avacta Completes £13M Sale Of Diagnostics Biz
British life sciences company Avacta Therapeutics said Tuesday that it has completed the £12.9 million ($16.6 million) cash sale of one of its two diagnostics businesses and its subsidiaries to Duomed...To view the full article, register now.
Already a subscriber? Click here to view full article